Key Highlights

  • Apimeds Pharmaceuticals US (NYSE American: APUS) shareholders approved a reverse stock split through written consent earlier this year.
  • The reverse stock split will become effective in the summer, replacing a previously announced spring date.
  • Trading on NYSE American will resume on a split‑adjusted basis under the same ticker symbol "APUS" at market open on the new effective day.
  • A new identifier will be assigned to the company’s common stock after the split.

Apimeds Pharmaceuticals US has cleared a key hurdle in its effort to consolidate its share structure. The biopharmaceutical firm secured majority shareholder backing for a reverse stock split, a move aimed at adjusting its stock price and trading dynamics.

Shareholder Vote Finalized

Apimeds Pharmaceuticals US shareholders formally approved a reverse stock split through written consent earlier this year. The decision followed the distribution of an information statement to investors, complying with regulatory requirements under the Securities Exchange Act. The approval paves the way for the company to amend its corporate charter.

Regulatory Waiting Period

The reverse stock split will not take effect immediately after shareholder approval. A mandatory statutory waiting period followed the mailing of the definitive information statement. This interval has now concluded, allowing the company to proceed with the next steps in the process.

New Effective Timing Set

Apimeds Pharmaceuticals US has rescheduled the reverse stock split’s effective timing to the upcoming summer. The change replaces an earlier planned date in the spring. The split will activate shortly after midnight Eastern time on the new day, with trading adjustments to follow at market open.

Trading Adjustments Expected

Once the reverse stock split takes effect, multiple existing shares of Apimeds Pharmaceuticals US common stock will convert into a single share. The company’s stock will continue trading on NYSE American under the ticker symbol "APUS," but on a split‑adjusted basis. Investors should note the change in share count and potential price impact.

Corporate Filing Timeline

The company plans to file the amended certificate of incorporation with Delaware’s Secretary of State shortly before the effective day. This filing will formally enact the reverse stock split. Apimeds Pharmaceuticals US will confirm the split’s completion in a subsequent regulatory filing once the effective day arrives.

Identifier Update

Following the reverse stock split, Apimeds Pharmaceuticals US will adopt a new identifier for its common stock. The change reflects the updated share structure and ensures accurate tracking of securities in clearing and settlement systems.

Next Steps for Investors

Shareholders should prepare for the automatic conversion of their holdings in the summer. The company has not indicated any further delays, but investors should monitor official announcements for confirmation of the split’s completion.

This article is for informational purposes only and does not constitute financial advice. Please consult a licensed financial adviser before making investment decisions.